BioMarin Pharmaceutical
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
105 Digital Dr, Novato, California, 9494...Phone Number
(415) 506-6700Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About BioMarin Pharmaceutical
BioMarin offers the RareConnections support program, designed to assist patients and caregivers navigating rare diseases. The program provides resources and support tailored to the needs of individuals affected by rare conditions. BioMarin also engages with healthcare professionals to enhance understanding and care for these patients. Their commitment is to provide real support for rare journeys.Explore more
BioMarin Pharmaceutical Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioMarin Pharmaceutical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if BioMarin Pharmaceutical has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on BioMarin Pharmaceutical recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if BioMarin Pharmaceutical is spiking on competitors!
Funding: Get notified immidiatlly once BioMarin Pharmaceutical has new funding data
Product Launch: Get notified when BioMarin Pharmaceutical launches new products
Click to see if BioMarin Pharmaceutical had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at BioMarin Pharmaceutical
BioMarin Pharmaceutical, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at BioMarin Pharmaceutical
Find more new buyers
Compare Similar Companies to BioMarin Pharmaceutical
Compare insights from companies similar to BioMarin Pharmaceutical, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
BioMarin Pharmaceutical
<$5M
11-50
Private
-
2019
AD
Aleisha DobbinsAssociate Director, Regulatory Training & Policy
Company Profile Activity
Activity Insights
BioMarin Pharmaceutical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioMarin Pharmaceutical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioMarin Pharmaceutical.
BioMarin Pharmaceutical Tech Stack
A closer look at the technologies used by BioMarin Pharmaceutical
See more technologies
BioMarin Pharmaceutical News & Media
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet alone FDA PDUFA target action date of Feb. 28, 2026 SAN RAFAEL, Calif., Oct. 29, 2025 /PRNewswire/ -- BioMarin Pharmaceutical...BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ BioMarin's planned submission to global health authorities on track for second half of 2025 SAN RAFAEL, Calif., Sept. 6, 2025 /PRNewswire/ -- BioMarin...News Details - BioMarin Pharmaceutical Inc. - Investor Relations
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive new data from studies of VOXZOGO ® (vosoritide) in children with achondroplasia and in ongoing clinical trials investigating other skeletal conditions, as well as PALYNZIQ ® (pegvaliase-pqpz) in adults with phenylketonuria (PKU). The latest findings further validate the long-term benefit and established safety profiles of both medicines, which continue to play a pivotal role for people living with these genetically defined condBioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
New data also to be presented for PALYNZIQ® (pegvaliaise-pqpz), reinforcing its value in sustaining blood Phe level reduction and improving health-related quality of life for adults with phenylketonuria SAN RAFAEL, Calif., March 20, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc....
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioMarin Pharmaceutical
Sign Up For FreeTo access detailed company insights
BioMarin offers the RareConnections support program, designed to assist patients and caregivers navigating rare diseases. The program provides resources and support tailored to the needs of individuals affected by rare conditions. BioMarin also engages with healthcare professionals to enhance understanding and care for these patients. Their commitm... Read More
